Crohn's and MS breakthrough

Main Category: Crohn's / IBD
Also Included In: Multiple Sclerosis
Article Date: 24 Feb 2004 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 stars

3.75 (4 votes)

Healthcare Prof:not yet rated


There is a new drug called Antegren which seems to be effective against Crohn's and Multiple Sclerosis.

Producers of the drug say that they are in the final stages of their clinical trials.

They say the new drug should be on the market next year.

The drug works by blocking the cells which are responsible for inflammation. It fights the symptoms of auto-immune disease.

In Multiple Sclerosis molecules on immune cells direct them to certain areas. This causes chronic inflammation. The same happens with Crohn's disease.

Antegren stops this from happening. It stops the molecules from reaching their destinations in the gut (and also the brain).

In the trials the drug, Antegren, was 30% more effective than a placebo. The same percentage improvement was found with both MS and Crohn's disease patients.

Article adapted by Medical News Today from original press release.
Visit our crohn's / ibd section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
n.p. "Crohn's and MS breakthrough." Medical News Today. MediLexicon, Intl., 24 Feb. 2004. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/6114.php>

APA
n.p. (2004, February 24). "Crohn's and MS breakthrough." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/6114.php.

Please note: If no author information is provided, the source is cited instead.




Crohn's / IBD

Most Popular Articles



Follow Our Crohn's News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Crohn's / IBD Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »